Alec Machiels - Jan 1, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Alec Machiels
Stock symbol
APLS
Transactions as of
Jan 1, 2024
Transactions value $
$344,075
Form type
4
Date filed
1/2/2024, 04:08 PM
Previous filing
Nov 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +3.34K +0.91% $0.00 371K Jan 1, 2024 Direct F1
holding APLS Common Stock 250K Jan 1, 2024 Indirect Owner (Bauhaus 1 LLC) F2
holding APLS Common Stock 12K Jan 1, 2024 Indirect Owner (Owned by Spouse) F3
holding APLS Common Stock 150K Jan 1, 2024 Indirect Owner (Spouse Trust) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $344K +5.75K $59.86 5.75K Jan 1, 2024 Common Stock 5.75K $59.86 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
F2 The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.
F3 Owned by spouse.
F4 On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee.
F5 This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.